Coronary artery atherosclerosis in patients with the initial and the early stage of chronic renal failure

• Authors: Piotr Bartnicki , Robert Stolarek , Jacek Rysz
• Languages of publication: EN

Abstracts

EN

The recent clinical data indicate that the initial and the early stages of chronic renal failure (CRF) may lead to increased incidence of cardiovascular complications and increased extent of coronary artery disease (CAD). This retrospective study was aimed to determine the effects of coexisting diabetes mellitus type 2 (DM-2) and the extent of atherosclerosis in coronary vessels in patients with mildly reduced kidney function (glomerular filtration rate GFR = 89–60 ml/min) and moderately reduced kidney function (GFR = 59–30 ml/min). The study patients included 53 subjects with creatinine concentration above 120 μmol/l as a cut-off level for the initial stage and compensated CRF. The distributions of coronary artery stenosis were also analysed with respect to DM-2 coexistence and levels of haemoglobin glikolised (HbA1c). The odds ratio of pathological changes in coronary arteries in patients with GFR = 44–30 ml/min, with respect to the number of affected vessels - only one, more than one or more than two - were 7.22, 4.90 and 3.55, respectively. In CRF patients with GFR = 60–89 ml/min the odds ratio of one, more than one and more than two vessels with stenosis and CAD was 1.93, 1.70 and 1.53, respectively. DM-2 was not related to the risk of significant coronary artery stenosis and did not enhance the pre-existing changes in the study setting. Our results demonstrate that the initial and the early stages of CRF were significant risk factors for coronary stenoses and for enhancing the pre-existing changes.

Keywords

EN

Chronic renal failure; Coronary artery disease

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 1
• Pages: 32-36

Dates

published

1 - 3 - 2009

online

11 - 2 - 2009

Contributors

author

Piotr Bartnicki

• Department of Nephrology, Hypertension and Family Medicine, Medical University, 90-549, Lodz, Poland

author

Robert Stolarek

• Department of Nephrology, Hypertension and Family Medicine, Medical University, 90-549, Lodz, Poland

author

Jacek Rysz

• Department of Nephrology, Hypertension and Family Medicine, Medical University, 90-549, Lodz, Poland

References

• [1] Foley R.N., Parfrey P.S., Sarnak M.J., Clinical epidemiology of cardiovascular disease in chronic renal disease, Am. J. Kidney Dis., 1998, 32, S112–S119 http://dx.doi.org/10.1053/ajkd.1998.v32.pm9820470[Crossref]
• [2] Levin A, Foley R.N., Cardiovascular disease in chronic renal insufficiency, Am. J. Kidney Dis., 2000, 36, S24–S30 http://dx.doi.org/10.1053/ajkd.2000.19928[Crossref]
• [3] Collins A.J., Cardiovascular mortality in end-stage renal disease, Am. J. Med. Sci., 2003, 325, 163–167 http://dx.doi.org/10.1097/00000441-200304000-00002[Crossref]
• [4] Levey A.S., Eknoyam G., Cardiovascular disease in chronic renal disease, Nephrol. Dial. Transplant., 1999, 14, 828–833 http://dx.doi.org/10.1093/ndt/14.4.828[Crossref]
• [5] Harnett J.D., Foley R.N., Kent G.M., Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors, Kidney Int., 1995, 47, 884–890 http://dx.doi.org/10.1038/ki.1995.132[Crossref]
• [6] Sarnak M.J., Levey A.S., Schoolwerth A.C., Kidney disease as a risk factor for development of cardiovascular disease. A statement from the AHA councils on kidney in cardiovascular disease. High Blood Pressure Research, Clinical cardiology and epidemiology and prevention, Circulation, 1993, 108, 2154–2169 http://dx.doi.org/10.1161/01.CIR.0000095676.90936.80[Crossref]
• [7] Al-Ahmad A., Sarnak M.J., Salem D.N., Konstam M.A., Cause and management of heart failure in patients with chronic renal disease, Semin. Nephrol., 2001, 21, 3–12 http://dx.doi.org/10.1053/snep.2001.18367[Crossref]
• [8] Horl W.H., Atherosclerosis and uremic retention solutes, Nephrology Forum, Kidney Int., 2004, 66, 1719–1731 http://dx.doi.org/10.1111/j.1523-1755.2004.00944.x[Crossref]
• [9] Sorensen C.R., Brendorp B., Rask-Madsen C., The prognostic importance of creatinine clearance after acute myocardial infarction, Eur. Heart J., 2002, 23, 948–952 http://dx.doi.org/10.1053/euhj.2001.2989[Crossref]
• [10] Tokmakova M.P., Skali H., Kenchaiah S., Chronic kidney disease, cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival and Ventricular Enlargement (SAVE) study, Circulation, 2004, 110, 3667–3673 http://dx.doi.org/10.1161/01.CIR.0000149806.01354.BF[Crossref]
• [11] Anavekar N.S., McMurray J.J.V., Velazquez E.J., Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction, N. Engl. J. Med., 2004, 351, 1285–1295 http://dx.doi.org/10.1056/NEJMoa041365[Crossref]
• [12] Amann K., Tyralla K., Cardiovascular changes in chronic renal failure - pathogenesis and therapy, Clinical Nephrol., 2002, 58, S62–S72
• [13] Dries D.L., Exner D.V., Domanski M.J., The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction, J. Am. Coll. Cardiol., 2000, 35, 681–689 http://dx.doi.org/10.1016/S0735-1097(99)00608-7[Crossref]
• [14] Go A.S., Chertow G.M., Fan D., Chronic kidney disease and the risks of death, cardiovascular events and hospitalisation, N. Engl. J. Med., 2004, 351, 1296–1305 http://dx.doi.org/10.1056/NEJMoa041031[Crossref]
• [15] Munter P., He J., Hamm L., Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States, J. Am. Soc. Nephrol., 2002, 13, 745–753
• [16] Rysz J., Banach M., Stolarek R.A., Pasnik J., Cialkowska-Rysz A., Koktysz R., et al., Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy, J. Nephrol., 2007., 20, 444–52
• [17] Selcoki Y., Turgut F., Kanbay M., Ozkara A., Tekin O., Uz B., et al., Cardiac valve calcifications and predictive parameters in hemodialysis patients, Cent. Eur. J. Med., 2007, 2, 304–31 http://dx.doi.org/10.2478/s11536-007-0026-2[Crossref][WoS]
• [18] Rysz J., Błaszczak R., Banach M., Kedziora-Kornatowska K., Kornatowski T., Tański W., et al., Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation, Arch. Immunol. Ther. Exp., 2007, 55, 335–40 http://dx.doi.org/10.1007/s00005-007-0033-7[WoS][Crossref]
• [19] Bachórzewska-Gajewska H., Małyszko J., Sitniewska E., Małyszko J., Dobrzycki S., Prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary interventions in everyday clinical practice, Arch. Med. Sci., 2006, 2, 256–261
• [20] Rysz J., Kocur E., Blaszczak R., Bartnicki P., Stolarek R.A., Piechota M., IL-2, IL-6 and IL-8 levels remain unaltered in the course of immunosuppressive therapy after renal transplantation, Cent. Eur. J. Med., 2008, 3, 199–202 http://dx.doi.org/10.2478/s11536-008-0011-4[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-008-0081-3